Osanni Bio is a biotechnology company developing therapies aimed at preventing and reversing blindness caused by retinal diseases.
Osanni Bio has raised $190.0M in total funding. The most recent round was Series B. The last funding was announced in June 2026.
Osanni Bio's investors include Patient Square Capital, Invus Opportunities, Retinal Degeneration Fund, Horowitz Group.
Osanni Bio is headquartered in San Francisco, United States.
Osanni Bio is a biotechnology company developing therapies aimed at preventing and reversing blindness caused by retinal diseases.
Osanni Bio is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Osanni Bio — Funding & Investors." VCBacked, June 23, 2026, https://www.vcbacked.co/company/osanni-bio. Accessed October 1, 2026.
VCBacked. (2026). Osanni Bio — Funding & Investors. Retrieved October 1, 2026, from https://www.vcbacked.co/company/osanni-bio
{{cite web |title=Osanni Bio — Funding & Investors |url=https://www.vcbacked.co/company/osanni-bio |website=VCBacked |access-date=October 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated